Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,456.00    -7.00 (-0.48%)
Bid:
1,467.00
Ask:
1,471.00
Spread: 4.00 (0.273%)
Market Cap: £3.09b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director/PDMR Shareholding

10 Apr 2018 14:34

RNS Number : 4612K
Hikma Pharmaceuticals Plc
10 April 2018
 

 

Hikma Pharmaceuticals PLC - EIP Awards

LONDON, 10 April 2018: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards on 10 April 2015 under the 2014 Executive Incentive Plan ("EIP") which was completed on10 April 2018. These awards were automatically exercised by operation of the conditional award and vesting process. The exercise price under the EIP is £nil.

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Bassam Kanaan

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bassam Kanaan

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Shares acquired from vesting of the conditional awards on10 April 2018 under the EIP.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 19,945

d)

Aggregated information

N/A

e)

Date of the transaction

10 April 2018

f)

Place of the transaction

London Stock Exchange (XLON)

 

Khalid Nabilsi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Khalid Nabilsi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Shares acquired from vesting of the conditional awards on10 April 2018 under the EIP.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 14,165

d)

Aggregated information

N/A

e)

Date of the transaction

10 April 2018

f)

Place of the transaction

London Stock Exchange (XLON)

Riad Mishlawi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Riad Mishlawi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Shares acquired from vesting of the conditional awards on10 April 2018 under the EIP.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 13,811

d)

Aggregated information

N/A

e)

Date of the transaction

10 April 2018

f)

Place of the transaction

London Stock Exchange (XLON)

 

 

Majda Labadi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Majda Labadi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Shares acquired from vesting of the conditional awards on10 April 2018 under the EIP.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 10,089

d)

Aggregated information

N/A

e)

Date of the transaction

10 April 2018

f)

Place of the transaction

London Stock Exchange (XLON)

 

Peter SpeirsCompany Secretary, responsible for releasing this announcement+44 (0) 20 7399 2760

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBXGDSXXBBGIG
Date   Source Headline
29th Apr 20225:05 pmRNSCorrection statement re Opiant
29th Apr 20227:15 amRNSTrading Statement
28th Apr 20226:05 pmRNSTransaction in Own Shares
27th Apr 20226:17 pmRNSTransaction in Own Shares
27th Apr 20227:00 amRNSTransaction in Own Shares
25th Apr 20226:04 pmRNSTransaction in Own Shares
25th Apr 20223:42 pmRNSResult of AGM
25th Apr 20227:00 amRNSNotice of GM
22nd Apr 20226:15 pmRNSTransaction in Own Shares
21st Apr 20226:06 pmRNSTransaction in Own Shares
21st Apr 20222:15 pmRNSAcquisition
20th Apr 20225:59 pmRNSTransaction in Own Shares
20th Apr 20227:00 amRNSFTC preliminary approval for Custopharm
19th Apr 20225:49 pmRNSTransaction in Own Shares
14th Apr 20225:35 pmRNSTransaction in Own Shares
13th Apr 20225:19 pmRNSTransaction in Own Shares
12th Apr 20225:55 pmRNSTransaction in Own Shares
12th Apr 20225:49 pmRNSDirector/PDMR Shareholding
11th Apr 20226:09 pmRNSTransaction in Own Shares
11th Apr 20227:00 amRNSShare Buyback Programme
8th Apr 20225:16 pmRNSTransaction in Own Shares
7th Apr 20225:53 pmRNSTransaction in Own Shares
5th Apr 20225:59 pmRNSTransaction in Own Shares
4th Apr 20226:09 pmRNSTransaction in Own Shares
1st Apr 20226:13 pmRNSTransaction in Own Shares
1st Apr 20225:46 pmRNSBlock listing Interim Review
31st Mar 20226:09 pmRNSTransaction in Own Shares
30th Mar 20225:57 pmRNSTransaction in Own Shares
30th Mar 202212:54 pmRNSTransaction in Own Shares
28th Mar 20226:09 pmRNSTransaction in Own Shares
25th Mar 20225:55 pmRNSTransaction in Own Shares
24th Mar 20226:03 pmRNSTransaction in Own Shares
23rd Mar 20225:08 pmRNSTransaction in Own Shares
22nd Mar 20226:03 pmRNSTransaction in Own Shares
21st Mar 20225:58 pmRNSTransaction in Own Shares
18th Mar 20226:32 pmRNSTransaction in Own Shares
17th Mar 20226:03 pmRNSTransaction in Own Shares
17th Mar 202210:00 amRNSAnnual Financial Report
16th Mar 20225:48 pmRNSTransaction in Own Shares
15th Mar 20225:51 pmRNSTransaction in Own Shares
15th Mar 202210:58 amRNSDirector/PDMR Shareholding
14th Mar 20226:23 pmRNSTransaction in Own Shares
11th Mar 20226:11 pmRNSTransaction in Own Shares
10th Mar 20225:48 pmRNSTransaction in Own Shares
9th Mar 20225:53 pmRNSTransaction in Own Shares
8th Mar 20225:21 pmRNSTransaction in Own Shares
8th Mar 202210:21 amRNSHolding(s) in Company
7th Mar 20225:12 pmRNSTransaction in Own Shares
7th Mar 20221:36 pmRNSDirector/PDMR Shareholding
4th Mar 20226:20 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.